Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

TransMedics (TMDX) EBIAT (2018 - 2026)

TransMedics has reported EBIAT over the past 8 years, most recently at $105.4 million for Q4 2025.

  • For Q4 2025, EBIAT rose 1436.87% year-over-year to $105.4 million; the TTM value through Dec 2025 reached $190.3 million, up 436.58%, while the annual FY2025 figure was $190.3 million, 436.58% up from the prior year.
  • EBIAT for Q4 2025 was $105.4 million at TransMedics, up from $24.3 million in the prior quarter.
  • Over five years, EBIAT peaked at $105.4 million in Q4 2025 and troughed at -$25.4 million in Q3 2023.
  • A 5-year average of $6.0 million and a median of -$1.8 million in 2023 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: crashed 242.34% in 2023 and later surged 1436.87% in 2025.
  • Year by year, EBIAT stood at -$12.7 million in 2021, then soared by 46.95% to -$6.7 million in 2022, then skyrocketed by 159.99% to $4.0 million in 2023, then skyrocketed by 70.11% to $6.9 million in 2024, then surged by 1436.87% to $105.4 million in 2025.
  • Business Quant data shows EBIAT for TMDX at $105.4 million in Q4 2025, $24.3 million in Q3 2025, and $34.9 million in Q2 2025.